Literature DB >> 3043777

Recipient preparation for bone marrow transplantation. I. Efficacy of total-body irradiation and busulfan.

P Mauch1, J D Down, M Warhol, S Hellman.   

Abstract

The efficacy of total body irradiation and busulfan were studied in recipient preparation for bone marrow transplantation. Male C57BL/6 (B6) mice were prepared for BMT with fractionated TBI or busulfan given in 4 equal doses over 3 days. Both TBI and busulfan are potent stem-cell killers. Both agents resulted in an exponential decrease in CFUs survival with increasing dose down to a 1 x 10(-4) CFUs survival. There appeared to be no break in the curve for either agent. Extrapolated fractional CFUs survival, as related to equivalent donor marrow engraftment or to equivalent 30-day survival without marrow transplantation, appeared lower for TBI as compared to busulfan. This may be due to the effect of busulfan and TBI on different stem-cell populations. Erythroid engraftment was tested after transplanting H-2 compatible LP marrow cells into treated B6 recipients. Greater than 80% of animals demonstrated complete engraftment with 3.4 mg busulfan or 1640 cGy TBI. At these 2 doses, the rate of recovery of donor marrow cellularity and CFUs content in treated recipients were identical for both preparative agents such that a selective effect on the host hematopoietic microenvironment harmful to engraftment was not seen. Complete engraftment in 100% of busulfan-prepared animals could not be achieved as such doses resulted in severe and fatal pulmonary vascular injury at 7-12 weeks posttransplant.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3043777     DOI: 10.1097/00007890-198808000-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

1.  Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities.

Authors:  Jennifer E Adair; Xin Zhao; Sylvia Chien; Min Fang; Martin E Wohlfahrt; Grant D Trobridge; Jason A Taylor; Brian C Beard; Hans-Peter Kiem; Pamela S Becker
Journal:  J Mol Med (Berl)       Date:  2012-06-03       Impact factor: 4.599

2.  The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity.

Authors:  W E Fitzsimmons; R Ghalie; H Kaizer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Human B cell development and antibody production in humanized NOD/SCID/IL-2Rγ(null) (NSG) mice conditioned by busulfan.

Authors:  Bongkum Choi; Eunyoung Chun; Miyoung Kim; Seong-Tae Kim; Keejung Yoon; Ki-Young Lee; Sung Joo Kim
Journal:  J Clin Immunol       Date:  2010-10-28       Impact factor: 8.317

4.  Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model.

Authors:  Elizabeth M Kang; Matthew M Hsieh; Mark Metzger; Allen Krouse; Robert E Donahue; Michel Sadelain; John F Tisdale
Journal:  Exp Hematol       Date:  2006-02       Impact factor: 3.084

5.  Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair.

Authors:  Carrie Fathke; Lynne Wilson; Jonathan Hutter; Vishal Kapoor; Andria Smith; Anne Hocking; Frank Isik
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

6.  Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice.

Authors:  Alex H Chang; Matthias T Stephan; Leszek Lisowski; Michel Sadelain
Journal:  Mol Ther       Date:  2008-08-05       Impact factor: 11.454

7.  Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation.

Authors:  Shuichi Ashizuka; William H Peranteau; Satoshi Hayashi; Alan W Flake
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

8.  Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age.

Authors:  H Vaziri; W Dragowska; R C Allsopp; T E Thomas; C B Harley; P M Lansdorp
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice.

Authors:  Jun Hayakawa; Matthew M Hsieh; Naoya Uchida; Oswald Phang; John F Tisdale
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

10.  Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts.

Authors:  Matthew M Hsieh; Saskia Langemeijer; Aisha Wynter; Oswald A Phang; Elizabeth M Kang; John F Tisdale
Journal:  Exp Hematol       Date:  2007-07-09       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.